Key result
ODBG-P-RVn demonstrated 20-fold greater antiviral activity than GS-441524 and near-equivalent activity to remdesivir in primary-like human small airway epithelial cells against multiple viruses.
Why the study?
Intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients.
ODBG-P-RVn is a promising orally available prodrug of remdesivir with broad-spectrum in vitro antiviral activity comparable to intravenous remdesivir, warranting further in vivo investigation.
Encourages oral prodrug development for broader antiviral access; leaves open clinical translation from in vitro data.
The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.
No takes yet. Share an insight, caveat, or question.
Lo et al. (2021) studied Viral infections (including SARS-CoV-2, Ebola, Nipah). ODBG-P-RVn vs. Remdesivir (RDV) and GS-441524 (RVn) was evaluated on Antiviral activity (EC50). ODBG-P-RVn demonstrated 20-fold greater antiviral activity than GS-441524 and near-equivalent activity to remdesivir in primary-like human small airway epithelial cells against multiple viruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: